The Oncology Institute, Inc.
TOI · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 7.73 | 0.98 | -0.02 | 0.02 |
| FCF Yield | -0.39% | -0.60% | -6.05% | 10.40% |
| EV / EBITDA | -264.49 | -210.92 | -12.30 | -9.40 |
| Quality | ||||
| ROIC | -7.66% | -10.87% | -8.91% | -9.37% |
| Gross Margin | 13.85% | 14.61% | 16.52% | 14.60% |
| Cash Conversion Ratio | 0.77 | 0.73 | 0.25 | -0.32 |
| Growth | ||||
| Revenue 3-Year CAGR | 14.16% | 13.17% | 13.81% | 15.93% |
| Free Cash Flow Growth | -15.99% | -114.64% | -318.68% | 99.10% |
| Safety | ||||
| Net Debt / EBITDA | 0.02 | -7.79 | -5.12 | -7.13 |
| Interest Coverage | -4.19 | -6.00 | -1.78 | -10.21 |
| Efficiency | ||||
| Inventory Turnover | 6.23 | 6.48 | 7.08 | 8.53 |
| Cash Conversion Cycle | 26.71 | 24.97 | 25.28 | 28.68 |